Tarsus Pharmaceuticals, Inc. Income Statement

Income Statement Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 57.03M25.82M17.45M182.95M
Cost of Revenue 2.08M0.95M1.59M12.83M
Gross Profit 54.95M24.86M15.85M170.13M
Operating items
Research & Development 18.83M41.71M42.62M50.31M53.39M
Selling, General & Administrative 8.17M25.40M44.95M108.70M237.31M
Other Operating Expenses 2.08M0.95M1.59M12.83M
Operating Expenses 27.00M69.18M88.53M160.60M303.52M
Operating Income -27.00M-12.16M-62.71M-143.16M-120.57M
EBIT -27.00M-12.16M-62.71M-143.16M-120.57M
Non-operating items
Interest & Investment Income 0.19M0.04M3.50M10.34M15.01M
Other Non Operating Income -0.99M-0.50M0.12M-1.94M
Non Operating Income 0.19M-1.61M0.62M7.26M5.01M
Net income details
EBT -26.81M-13.77M-62.09M-135.89M-115.55M
Tax Provisions 0.00M0.06M-0.00M
Profit After Tax -26.81M-13.83M-62.09M-135.89M-115.55M
Equity Income -0.59M-0.27M0.26M-0.59M
Income from Continuing Operations -26.81M-13.83M-62.09M-135.89M-115.55M
Consolidated Net Income -26.81M-13.83M-62.09M-135.89M-115.55M
Income towards Parent Company -26.81M-13.83M-62.09M-135.89M-115.55M
Net Income towards Common Stockholders -26.81M-13.83M-62.09M-135.89M-115.55M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 20.32M20.68M26.67M33.10M38.23M
Shares Outstanding (Diluted Average) 6.21M20.55M24.62M29.38M37.60M
EBITDA -26.81M-13.83M-62.16M-135.82M-115.37M
Tax Rate 0.01%